These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25065441)

  • 1. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility.
    Cuesta-Mateos C; Colom-Fernández B; Portero-Sainz I; Tejedor R; García-García C; Concha-Garzón MJ; De las Heras-Alonso ME; Martínez MA; Juarez C; Muñoz-Calleja C
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):482-9. PubMed ID: 25065441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
    Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
    J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.
    Sato S; Hirakata M; Kuwana M; Suwa A; Inada S; Mimori T; Nishikawa T; Oddis CV; Ikeda Y
    Arthritis Rheum; 2005 May; 52(5):1571-6. PubMed ID: 15880816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
    Kang EH; Nakashima R; Mimori T; Kim J; Lee YJ; Lee EB; Song YW
    BMC Musculoskelet Disord; 2010 Sep; 11():223. PubMed ID: 20875136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
    Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
    Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New autoantibodies in dermatomyositis].
    Bielsa I
    Actas Dermosifiliogr; 2009 Apr; 100(3):182-9. PubMed ID: 19457303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody].
    Nagata K; Tomii K; Nanjo S; Kubota M; Tachikawa R; Nishio M
    Nihon Kokyuki Gakkai Zasshi; 2011 Jan; 49(1):30-6. PubMed ID: 21384679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
    Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
    J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
    Hirakata M
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Dec; 30(6):444-54. PubMed ID: 18174673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of HRCT in myositis-associated interstitial lung disease.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Aihara K; Ikezoe K; Watanabe K; Taguchi Y; Hatta K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
    Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
    Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.